TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7645436

Group type: EXPERIMENTAL
Intervention: Large volume spacers (LVSs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metered-dose inhalers (MDIs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 40
Study: 2496075

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 7
Study: 138557

Group type: EXPERIMENTAL
Intervention: 0.025% betamethasone benzoate gel
Number of subjects: 121

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 121
Study: 31364343

Group type: EXPERIMENTAL
Intervention: Classical method (using sharp dissection)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ultrasonic cautery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 28102456

Group type: EXPERIMENTAL
Intervention: Ranibizumab bimonthly (RABIMO group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ranibizumab PRN (PRN group)
Number of subjects: 40
Study: 25647654

Group type: EXPERIMENTAL
Intervention: Supramaximal Interval Training (SMIT) - 10 × 30-second intervals at 150% of the peak power output (PPO) with 4-minute rest
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 8 × 2.5-minute intervals at 90% of the peak power output (PPO) with 3-minute rest
Number of subjects: 20
Study: 22669627

Group type: EXPERIMENTAL
Intervention: Po-husk (14 g/day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose 14 g/day)
Number of subjects: 178
Study: 21411833

Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 10
Study: 19457565

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 268

Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 268
Study: 16362803

Group type: EXPERIMENTAL
Intervention: Active anal stimulation at 35 Hz
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham stimulation at 1 Hz
Number of subjects: 90
Study: 15130646

Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lens (IOL) implantation with primary posterior continuous curvilinear capsulorhexis (PCCC) and anterior vitrectomy in Group 1 (n = 37)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with no PCCC in Group 2A (n = 37)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with PCCC and no vitrectomy in Group 2BN (n = 14)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with PCCC and vitrectomy in Group 2BV (n = 15)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall results for AcrySof IOL implantation
Number of subjects: 72
Study: 11697018

Group type: EXPERIMENTAL
Intervention: LW 50020 (oral immunomodulator containing antigens of seven bacteria common in RTIs)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard schedule (immunization cycle + one booster cycle)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Two consecutive booster cycles
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: LW 50020
Number of subjects: 188
Study: 9131882

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 48
Study: 7910237

Group type: EXPERIMENTAL
Intervention: Bilateral compression ultrasound
Number of subjects: 100
Study: 3293699

Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay rapid test
Number of subjects: 250

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 250

Group type: COMPARATOR
Intervention: Previous prescribing decisions
Number of subjects: 250
Study: 31464152

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deutetrabenazine 36 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 0
Study: 28166613

Group type: EXPERIMENTAL
Intervention: Biological agents (etanercept, infliximab, adalimumab)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional drugs (methotrexate, cyclosporin)
Number of subjects: 129
Study: 24705615

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 22038536

Group type: EXPERIMENTAL
Intervention: 7-mg nicotine patch
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20334663

Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nateglinide (270 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 30
Study: 17645591

Group type: EXPERIMENTAL
Intervention: Exercise; supervised endurance exercise three times a week.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no exercise, dietary advice or no advice).
Number of subjects: 188
Study: 16133653

Group type: EXPERIMENTAL
Intervention: Combined weight-bearing training program (50 min, twice a week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 12112165

Group type: EXPERIMENTAL
Intervention: Presence of white matter hyperintensities (WMH)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Deep white matter changes
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Periventricular changes
Number of subjects: 108

Group type: COMPARATOR
Intervention: Baseline reaction time and switch‐cost
Number of subjects: 108
Study: 10089837

Group type: EXPERIMENTAL
Intervention: First shock at twice DFT plus, second to fifth shocks at maximum output (34 J)
Number of subjects: 166

Group type: COMPARATOR
Intervention: All shocks programmed at 34 J
Number of subjects: 166
Study: 11995907

Group type: EXPERIMENTAL
Intervention: Heat‐and‐moisture‐retaining masks
Number of subjects: 10

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 10
Study: 2189613

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7447618

Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 26
Study: 30975217

Group type: EXPERIMENTAL
Intervention: PEEP of 10 cmH2O with lung recruitment maneuvers (RM)
Number of subjects: 2378

Group type: COMPARATOR
Intervention: PEEP of 5 cmH2O without recruitment maneuvers (RM)
Number of subjects: 2378
Study: 27884660

Group type: EXPERIMENTAL
Intervention: Exenatide (10μg BID)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 26163609

Group type: COMPARATOR
Intervention: Tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tailored triple therapy plus pretreatment with probiotic containing yogurt
Number of subjects: 200
Study: 23646471

Group type: EXPERIMENTAL
Intervention: Baidanhang lavage fluid nasal irrigation (BLFNI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiologic saline with dexamethasone and gentamycin (Control)
Number of subjects: 90
Study: 21861690

Group type: EXPERIMENTAL
Intervention: Electromagnetic‐Own‐Signal‐Treatment (EMOST)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 15
Study: 19761114

Group type: EXPERIMENTAL
Intervention: Ear-electroacupuncture (Ear-EA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Body-electroacupuncture (body-EA)
Number of subjects: 80
Study: 17208119

Group type: EXPERIMENTAL
Intervention: 4-month program (weight loss, low-sodium diet, high in fruit, vegetables, and fish, increased physical activity)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 4-month program
Number of subjects: 241
Study: 16573544

Group type: EXPERIMENTAL
Intervention: Neoadjuvant doxorubicin (10 mg/m² weekly, starting from acceptance onto the waiting list for LT, with one intraoperative dose of 15 mg/m² and postoperative doses depending on clinical course, up to a cumulative dose of 400 mg/m²)
Number of subjects: 46

Group type: COMPARATOR
Intervention: LT alone (control group)
Number of subjects: 46
Study: 14520776

Group type: EXPERIMENTAL
Intervention: Tooth whitening gel containing 25% carbamide peroxide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tooth whitening gel containing 8.7% hydrogen peroxide
Number of subjects: 59
Study: 10582982

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Stroke Education Program (SEP)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional stroke unit care
Number of subjects: 204
Study: 8753940

Group type: EXPERIMENTAL
Intervention: Increasing interstimulus interval (ISI) during noxious sural nerve stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noxious sural nerve stimulation
Number of subjects: 0
Study: 1812432

Group type: EXPERIMENTAL
Intervention: Cuban vaccine against group B Neisseria meningitidis
Number of subjects: 106000
Study: 6341912

Group type: EXPERIMENTAL
Intervention: ICRF 159 plus radiotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo plus radiotherapy
Number of subjects: 70
Study: 29532416

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and 800 mg inulin) for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 60
Study: 28859679

Group type: EXPERIMENTAL
Intervention: Walking at lunch
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Regular face-to-face interaction
Number of subjects: 478

Group type: COMPARATOR
Intervention: Private offices
Number of subjects: 478
Study: 25074734

Group type: EXPERIMENTAL
Intervention: 12-month aerobic walking group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Strengthening and flexibility group
Number of subjects: 179
Study: 22373777

Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus modified glass ionomer restoration (CTG+R)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Connective tissue graft only (CTG)
Number of subjects: 34
Study: 21721073

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 42
Study: 19820754

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril 20 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACE inhibitor + Angiotensin receptor blocker (lisinopril 10 mg/day + candesartan 16 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (eplerenone 25 mg/day)
Number of subjects: 12
Study: 16384629

Group type: EXPERIMENTAL
Intervention: Patients with medial frontal lobe damage (ACC involvement)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls (age and education matched)
Number of subjects: 2
Study: 16335646

Group type: EXPERIMENTAL
Intervention: Low-dose quinine (10 mg/kg 2 times/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard quinine (10 mg/kg 3 times/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 11077029

Group type: EXPERIMENTAL
Intervention: Rifampicin 1200 mg/day in two divided doses
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 46
Study: 9217894

Group type: EXPERIMENTAL
Intervention: Insulin with saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin with indomethacin (0.65 microgram/kg/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin with L-NMMA (30 micrograms/kg/min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin with propranolol (0.2 microgram/kg/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Indomethacin (0.65 microgram/kg/min) alone
Number of subjects: 15

Group type: COMPARATOR
Intervention: L-NMMA (30 micrograms/kg/min) alone
Number of subjects: 15
Study: 8453955

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2422461

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (definite infarction subgroup)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous digoxin (definite infarction subgroup)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 34
Study: 27960578

Group type: EXPERIMENTAL
Intervention: Sutureless scleral tunnel trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 34
Study: 27770820

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with 12 once-weekly sessions and voucher rewards for cannabis-free urinalysis
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 544

Group type: COMPARATOR
Intervention: Optimised Treatment as Usual (OTAU) psychoeducational package
Number of subjects: 544
Study: 25653151

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii CNCM I-745
Number of subjects: 363
Study: 23905488

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg daily for 12 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (600 mg parenterally for 7 days, followed by 600 mg orally for 12 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both treatments (Transdermal testosterone and Alpha-lipoic acid)
Number of subjects: 45
Study: 21090960

Group type: EXPERIMENTAL
Intervention: SADV (coordinated substance abuse and domestic violence treatment program)
Number of subjects: 69

Group type: COMPARATOR
Intervention: TSF (Twelve Step Facilitation)
Number of subjects: 69
Study: 18355589

Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional saw and chisel osteotomies
Number of subjects: 50
Study: 17029131

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (single dose)
Number of subjects: 96
Study: 12683473

Group type: EXPERIMENTAL
Intervention: auto-nCPAP
Number of subjects: 35

Group type: COMPARATOR
Intervention: conventional nCPAP
Number of subjects: 35
Study: 12755665

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56
Study: 10573548

Group type: EXPERIMENTAL
Intervention: 15 mg oral vitamin A
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8561324

Group type: EXPERIMENTAL
Intervention: IV clonidine treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 24
Study: 1919058

Group type: EXPERIMENTAL
Intervention: SSR (solar-simulated radiation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SSR/S (solar-simulated radiation plus UVB sunscreen)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SSR/S/5‐MOP (solar-simulated radiation plus UVB sunscreen with 5-methoxypsoralen at 30 ppm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no SSR or topical treatment)
Number of subjects: 18
Study: 6882818

Group type: EXPERIMENTAL
Intervention: EMG plus thermal biofeedback
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 45

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 45
Study: 30712533

Group type: EXPERIMENTAL
Intervention: Active rTMS (15Hz) targeting the left PMC/DLPFC for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 0
Study: 30203386

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg for 5 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg with oseltamivir 75 mg for 5 days
Number of subjects: 18
Study: 29071880

Group type: EXPERIMENTAL
Intervention: Yimusake Tablets at 1.5 g per night for 8 weeks (group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dapoxetine hydrochloride at 30 mg 1-3 hours before sexual activity for 8 weeks (group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Yimusake Tablets plus dapoxetine hydrochloride for 8 weeks (group C)
Number of subjects: 180
Study: 24258250

Group type: EXPERIMENTAL
Intervention: Peer coaching intervention by trained coaches
Number of subjects: 109
Study: 23244155

Group type: EXPERIMENTAL
Intervention: Psychoeducational program (eight 90 minute weekly sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no psychoeducational intervention)
Number of subjects: 76
Study: 20648044

Group type: EXPERIMENTAL
Intervention: Higher intakes of mono- and polyunsaturated fat
Number of subjects: 2551

Group type: COMPARATOR
Intervention: Total fat intake or different types of fat
Number of subjects: 2551
Study: 17939477

Group type: EXPERIMENTAL
Intervention: Alumina-alumina bearing surfaces
Number of subjects: 140

Group type: COMPARATOR
Intervention: Metal-polyethylene bearing surfaces
Number of subjects: 140
Study: 15530585

Group type: EXPERIMENTAL
Intervention: Short bouts (SB; 3 x 10 min/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long bouts (LB; 30 min/day)
Number of subjects: 40
Study: 11898013

Group type: EXPERIMENTAL
Intervention: L5-S1 spinal manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Side-posture positioning (control)
Number of subjects: 24
Study: 9427568

Group type: EXPERIMENTAL
Intervention: Gln-PN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Gln-free PN
Number of subjects: 0
Study: 10150702

Group type: EXPERIMENTAL
Intervention: Medical malpractice cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negligent driving cases
Number of subjects: 0
Study: 2752040

Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 0.1 ng.kg‐1.min‐1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 1.0 ng.kg‐1.min‐1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 5.0 ng.kg‐1.min‐1
Number of subjects: 4

Group type: COMPARATOR
Intervention: Vehicle infusion (control)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (325 mg/d)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Endogenous TXB2 entry rate calculation
Number of subjects: 4
Study: 616222

Group type: EXPERIMENTAL
Intervention: lynestrenol 0.5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: lynestrenol 0.5 mg + ethinyl estradiol 0.05 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: d‐norgestrel 0.25 mg + ethinyl estradiol 0.05 mg
Number of subjects: 27
Study: 29605029

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with fluorouracil, epirubicin, and cyclophosphamide
Number of subjects: 122
Study: 28545625

Group type: EXPERIMENTAL
Intervention: Home-based walking program (intervention group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual-care group (control group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy sex- and age-matched participants (control for respiratory endurance variables)
Number of subjects: 54
Study: 26173528

Group type: EXPERIMENTAL
Intervention: Self-directed reflection on diagnoses
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pass 1 diagnoses
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Revised diagnoses
Number of subjects: 47
Study: 23030716

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/day) for 6 weeks before surgery
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no dutasteride)
Number of subjects: 142
Study: 21942303

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 18206394

Group type: EXPERIMENTAL
Intervention: Cortical depression fracture present
Number of subjects: 121

Group type: COMPARATOR
Intervention: No cortical depression fracture
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Older age at injury
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Meniscal tears
Number of subjects: 121
Study: 17190950

Group type: EXPERIMENTAL
Intervention: Immediate antiepileptic treatment
Number of subjects: 419

Group type: COMPARATOR
Intervention: Treatment only in the event of seizure recurrence
Number of subjects: 419
Study: 12701462

Group type: EXPERIMENTAL
Intervention: Aerobic group training three times a week for three months (n = 50)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 51)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Aerobic group training (n = 50)
Number of subjects: 93
Study: 11502779

Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (methylprednisolone; 15 mg/kg for four cycles and then 7.5 mg/kg for four cycles; each cycle consisted of two infusions on alternate days at 2‐wk intervals)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral glucocorticoids (prednisone; starting dose, 100 mg/d; withdrawal after 5 months)
Number of subjects: 82
Study: 9214325

Group type: EXPERIMENTAL
Intervention: Assisted laparoscopic resection (ALR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dissection-facilitated laparoscopic resection (DLR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Laparotomy (conversion from laparoscopic approach)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mean hospital stay
Number of subjects: 41
Study: 8500314

Group type: EXPERIMENTAL
Intervention: Recruitment via mass media
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Recruitment at worksites
Number of subjects: 577

Group type: COMPARATOR
Intervention: Recruitment at community events
Number of subjects: 577

Group type: COMPARATOR
Intervention: Direct mail recruitment
Number of subjects: 577